{
    "pmcid": "PMC3548984",
    "var_drug_ann": [
        {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23213055,
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "In Arm A (5 years tamoxifen), CYP2D6 poor metabolizers with 2 null alleles (PM/PM) had a significantly higher odds of a disease event (recurrence, contralateral breast cancer, second non-breast cancer, or death) compared with extensive metabolizers (EM/EM): OR=2.45, 95% CI: 1.05\u20135.73, p=0.04.",
            "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Associated with increased response to tamoxifen in terms of higher odds of a disease event in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
            "Alleles": "PM/PM",
            "Specialty Population": null,
            "Metabolizer types": "poor metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "response to",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "EM/EM",
            "Comparison Metabolizer types": "extensive metabolizer",
            "Citations": [
                "\u201cGenotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.\u201d",
                "\u201cIn Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05\u20135.73, p=0.04) and women with one poor allele (PM/IM or PM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07) had a higher likelihood of an event than women with two extensive alleles (EM/EM).\u201d",
                "\u201cAmong the post-menopausal women with ER positive breast cancer enrolled on ABCSG 8 who were randomized to 5 years of tamoxifen (Arm A), there was a significantly higher odds of a disease event for those with CYP2D6 PM/PM phenotype relative to those with the CYP2D6 EM/EM phenotype, but this was not observed in patients treated with anastrozole following tamoxifen (Arm B).\u201d"
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23213055,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "In Arm A (5 years tamoxifen), women with one poor allele (PM/IM or PM/EM) had a non-significant trend toward higher odds of a disease event compared with EM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07.",
            "Sentence": "CYP2D6 phenotypes PM/IM + PM/EM Are Not associated with increased response to tamoxifen in terms of higher odds of a disease event in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
            "Alleles": "PM/IM + PM/EM",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "response to",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "EM/EM",
            "Comparison Metabolizer types": "extensive metabolizer",
            "Citations": [
                "\"In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05\u20135.73, p=0.04) and women with one poor allele (PM/IM or PM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07) had a higher likelihood of an event than women with two extensive alleles (EM/EM).\"",
                "\"In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM (Table 5). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event.\"",
                "\"Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.\""
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23213055,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "In Arm A (5 years tamoxifen), women classified as EM/IM or IM/IM did not have increased odds of a disease event compared with EM/EM: OR=1.23, 95% CI: 0.58\u20132.61, p=0.60.",
            "Sentence": "CYP2D6 phenotypes EM/IM + IM/IM Are Not associated with increased response to tamoxifen in terms of higher odds of a disease event in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
            "Alleles": "EM/IM + IM/IM",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "response to",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "EM/EM",
            "Comparison Metabolizer types": "extensive metabolizer",
            "Citations": [
                "\"CYP2D6 phenotype groups were defined as previously published (11) where \u2018extensive\u2019 metabolizers do not carry a null or reduced allele (EM/EM); those with one to two reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \u2018poor\u2019 metabolizers, those with 2 null alleles (PM/PM).\"",
                "\"In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM (Table 5). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event.\"",
                "\"Tamoxifen is a weak anti-estrogen with agonistic properties that is extensively metabolized into potent anti-estrogens, 4-hydroxy tamoxifen and endoxifen\u2026 Endoxifen is formed by the CYP2D6-mediated oxidation of n-desmethyl tamoxifen\u2026 Common genetic variations in CYP2D6 and/or drug-induced inhibition of CYP2D6 enzyme activity are associated with significant reductions in endoxifen concentrations in tamoxifen treated humans (6\u20138).\""
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23213055,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "In the first 2 years of tamoxifen when all patients received tamoxifen, PM/PM showed a non-significant higher odds of a disease event relative to EM/EM: Arm A OR=2.54, p=0.25; Arm B OR=2.60, p=0.46.",
            "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Not associated with increased response to tamoxifen in terms of higher odds of a disease event during the first 2 years of therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
            "Alleles": "PM/PM",
            "Specialty Population": null,
            "Metabolizer types": "poor metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "response to",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "EM/EM",
            "Comparison Metabolizer types": "extensive metabolizer",
            "Citations": [
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.",
                "Conditional logistic regression modeling (CLRM) for matched triplets and pairs was used to examine whether the odds of a disease event differed with respect to CYP2D6 genotype in the following situations: 1) the first 5 years of treatment, for each arm separately 2) years 3\u20135 of treatment, for each arm separately, 3) in the first 2 years of treatment, (when all patients were assigned tamoxifen).",
                "There were a limited number of events during years 1\u20132 (Table 3); however, a similar non-significant higher odds of a disease event was observed for PM/PM relative to EM/EM in the first 2 years of tamoxifen for both arms: Arm A: OR = 2.54, p = 0.25 and Arm B: OR = 2.60, p = 0.46."
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23213055,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "During years 3\u20135 for women in Arm A who remained on tamoxifen, PM/PM had a non-significant trend toward increased odds of a disease event relative to EM/EM: OR=2.40, 95% CI: 0.86\u20136.66, p=0.09.",
            "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Not associated with increased response to tamoxifen in terms of higher odds of a disease event during years 3\u20135 of therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
            "Alleles": "PM/PM",
            "Specialty Population": null,
            "Metabolizer types": "poor metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "response to",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "EM/EM",
            "Comparison Metabolizer types": "extensive metabolizer",
            "Citations": [
                "In years 3\u20135 when patients remained on tamoxifen (Arm A) or switched to anastrozole (Arm B), PM/PM tended towards a higher likelihood of a disease event relative to EM/EM (OR= 2.40, 95% CI: 0.86\u20136.66, p=0.09) among women on Arm A but not among women on Arm B (OR= 0.28; 95% CI: 0.03\u20132.30).",
                "During years 3\u20135, for women on Arm A who remained event free during the first 2 years of tamoxifen therapy, PM/PM (OR 2.40, 95% CI: 0.86 to 6.66, p = 0.09) and IM/PM or EM/PM (OR 1.70, 95% CI: 0.91\u20133.17, p=0.09) had a trend towards an increased odds of a disease event relative to EM/EM."
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23213055,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "During years 3\u20135 for women in Arm A on continued tamoxifen, patients with at least one poor allele (IM/PM or EM/PM) had a non-significant trend towards increased odds of a disease event relative to EM/EM: OR=1.70, 95% CI: 0.91\u20133.17, p=0.09.",
            "Sentence": "CYP2D6 phenotypes EM/PM + PM/IM Are Not associated with increased response to tamoxifen in terms of higher odds of a disease event during years 3\u20135 of therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
            "Alleles": "EM/PM + PM/IM",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "response to",
            "Multiple drugs And/or": null,
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "EM/EM",
            "Comparison Metabolizer types": "extensive metabolizer",
            "Citations": [
                "During years 3\u20135, for women on Arm A who remained event free during the first 2 years of tamoxifen therapy, PM/PM (OR 2.40, 95% CI: 0.86 to 6.66, p = 0.09) and IM/PM or EM/PM (OR 1.70, 95% CI: 0.91\u20133.17, p=0.09) had a trend towards an increased odds of a disease event relative to EM/EM.",
                "In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM ([Table 5](#T5)). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event."
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen, anastrozole",
            "PMID": 23213055,
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "In Arm B (2 years tamoxifen followed by 3 years anastrozole), no significant association was found between CYP2D6 phenotype and the likelihood of a disease event during the 5 years of treatment. Specifically, PM/PM vs EM/EM: OR=0.60, 95% CI: 0.15\u20132.37, p=0.47; EM/PM + PM/IM vs EM/EM: OR=0.76, 95% CI: 0.43\u20131.31, p=0.32; EM/IM + IM/IM vs EM/EM: OR=1.02, 95% CI: 0.52\u20132.01, p=0.96.",
            "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Not associated with response to tamoxifen and anastrozole in terms of odds of a disease event over 5 years of sequential therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
            "Alleles": "PM/PM",
            "Specialty Population": null,
            "Metabolizer types": "poor metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "PD/PK terms": "response to",
            "Multiple drugs And/or": "and",
            "Population types": "in patients with",
            "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "EM/EM",
            "Comparison Metabolizer types": "extensive metabolizer",
            "Citations": [
                "Conversely in Arm B, no significant association was found between *CYP2D6* genotype and the likelihood of a disease event during the 5 years of treatment.",
                "|   | Tamoxifen only (Arm A) |  | Tamoxifen followed by anastrozole (Arm B) |  |\n| --- | --- | --- | --- | --- |\n|   | Odds Ratio (95% CI) | p-value | Odds Ratio (95% CI) | p-value |\n| PM/PM relative to EM/EM | 2.45 (1.05, 5.73) | 0.04 | 0.60 (0.15, 2.37) | 0.47 |\n| EM/PM and PM/IM relative to EM/EM | 1.67 (0.95, 2.93) | 0.07 | 0.76 (0.43, 1.31) | 0.32 |\n| EM/IM and IM/IM relative to EM/EM | 1.23 (0.58, 2.61) | 0.60 | 1.02 (0.52, 2.01) | 0.96 |",
                "For ABCSG 8 patients randomized to 2 years of tamoxifen followed by 3 years of anastrozole (Arm B), *CYP2D6* genotype was not associated with the odds of a disease event."
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
            },
            "Drug(s)_normalized": {
                "normalized": "anastrozole",
                "drug_id": "PA448432",
                "confidence": 1.0
            }
        }
    ],
    "var_fa_ann": [],
    "study_parameters": [
        {
            "Study Parameters ID": 1,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 319,
            "Study Controls": 557,
            "Characteristics": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 randomized to 5 years of tamoxifen (Arm A); association of CYP2D6 PM/PM phenotype vs EM/EM with disease event during 5 years of tamoxifen therapy",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.04",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.45,
            "Confidence Interval Start": 1.05,
            "Confidence Interval Stop": 5.73,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": 2,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 319,
            "Study Controls": 557,
            "Characteristics": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 randomized to 5 years of tamoxifen (Arm A); association of CYP2D6 EM/PM or PM/IM phenotypes vs EM/EM with disease event during 5 years of tamoxifen therapy",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.07",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.67,
            "Confidence Interval Start": 0.95,
            "Confidence Interval Stop": 2.93,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": 3,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 319,
            "Study Controls": 557,
            "Characteristics": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 randomized to 5 years of tamoxifen (Arm A); association of CYP2D6 EM/IM or IM/IM phenotypes vs EM/EM with disease event during 5 years of tamoxifen therapy",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.60",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.23,
            "Confidence Interval Start": 0.58,
            "Confidence Interval Stop": 2.61,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": 4,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 319,
            "Study Controls": 557,
            "Characteristics": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 randomized to 2 years of tamoxifen followed by 3 years of anastrozole (Arm B); association of CYP2D6 PM/PM phenotype vs EM/EM with disease event during 5 years of sequential therapy",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.47",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.6,
            "Confidence Interval Start": 0.15,
            "Confidence Interval Stop": 2.37,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": 5,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 319,
            "Study Controls": 557,
            "Characteristics": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 randomized to 2 years of tamoxifen followed by 3 years of anastrozole (Arm B); association of CYP2D6 EM/PM or PM/IM phenotypes vs EM/EM with disease event during 5 years of sequential therapy",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.32",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.76,
            "Confidence Interval Start": 0.43,
            "Confidence Interval Stop": 1.31,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": 6,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 319,
            "Study Controls": 557,
            "Characteristics": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 randomized to 2 years of tamoxifen followed by 3 years of anastrozole (Arm B); association of CYP2D6 EM/IM or IM/IM phenotypes vs EM/EM with disease event during 5 years of sequential therapy",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.96",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.02,
            "Confidence Interval Start": 0.52,
            "Confidence Interval Stop": 2.01,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": 7,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 319,
            "Study Controls": 557,
            "Characteristics": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 Arm A; CYP2D6 PM/PM vs EM/EM and odds of disease event during years 3\u20135 while continuing tamoxifen (among women event-free in first 2 years)",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.09",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.4,
            "Confidence Interval Start": 0.86,
            "Confidence Interval Stop": 6.66,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": 8,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 319,
            "Study Controls": 557,
            "Characteristics": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 Arm A; CYP2D6 EM/PM or PM/IM vs EM/EM and odds of disease event during years 3\u20135 while continuing tamoxifen (among women event-free in first 2 years)",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.09",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.7,
            "Confidence Interval Start": 0.91,
            "Confidence Interval Stop": 3.17,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": 9,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 319,
            "Study Controls": 557,
            "Characteristics": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 Arm B; CYP2D6 PM/PM vs EM/EM and odds of disease event during years 3\u20135 while on anastrozole after 2 years of tamoxifen (among women event-free in first 2 years)",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.23",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.28,
            "Confidence Interval Start": 0.03,
            "Confidence Interval Stop": 2.3,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": 10,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 319,
            "Study Controls": 557,
            "Characteristics": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 Arm B; CYP2D6 EM/PM or PM/IM vs EM/EM and odds of disease event during years 3\u20135 while on anastrozole after 2 years of tamoxifen (among women event-free in first 2 years)",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.22",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.63,
            "Confidence Interval Start": 0.31,
            "Confidence Interval Stop": 1.28,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        }
    ],
    "summary": "Study question and rationale:\nThis pharmacogenomic analysis asked whether germline CYP2D6 metabolizer status predicts outcomes in postmenopausal women with ER-positive early breast cancer treated with adjuvant tamoxifen, and whether any effect is specific to periods of tamoxifen exposure versus after switching to an aromatase inhibitor. The work responds to conflicting literature on CYP2D6\u2013tamoxifen associations and concerns about genotyping quality and trial design in prior negative studies.\n\nTrial and design:\n- Parent trial: ABCSG-8, a large, prospective, randomized, open-label study of 3,901 postmenopausal women with endocrine-responsive, early-stage, node-positive or node-negative, grade 1\u20132 breast cancer, treated without chemotherapy.\n- Arms:\n  - Arm A: 5 years tamoxifen 20 mg/day.\n  - Arm B: 2 years tamoxifen 20 mg/day \u2192 then 3 years anastrozole 1 mg/day.\n- Pharmacogenetic substudy: retrospective, matched case\u2013control within ABCSG-8 using archived paraffin blocks containing normal and tumor tissue.\n\nCases and controls:\n- Cases: women with an eligible first event during defined follow-up windows: local/regional/distant recurrence, contralateral breast cancer, second non-breast primary, or death (invasive DFS definition, STEEP criteria). Events beyond 5 years were excluded due to lack of systematic data on extended endocrine therapy and enrollment into a separate extension trial (ABCSG-16/SALSA).\n- Controls: for each case, 1\u20132 controls (optimal matching) from the same arm, with:\n  - Age within 5 years.\n  - Same surgical/radiation category (BCS\u00b1RT vs mastectomy\u00b1RT).\n  - Same tumor stage (I vs II/III) and nodal status (positive vs negative).\n  - Longer follow-up (time at risk) than the corresponding case.\n- Final dataset: 319 cases and 557 controls (238 cases with 2 controls; 81 with 1 control) from 1,589 patients with available tissue.\n\nCYP2D6 genotyping and phenotype assignment:\n- DNA source: three 10-\u00b5m whole-tissue sections from FFPE blocks containing both normal and tumor tissue, to mitigate artifactual loss of CYP2D6 signal from 22q13 loss of heterozygosity.\n- SNPs/alleles genotyped:\n  - Null (poor function) alleles: *3 (2549delA), *4 (1846G>A), *6 (1707delT).\n  - Reduced-function alleles: *10 (defined by 100C>T and 1846G>A haplotype), *41 (2988G>A).\n- CYP2D6 *5 (gene deletion) and duplications were not assessable due to FFPE DNA fragmentation; multiple quality controls and TaqMan assay validation were used.\n- Phenotype categories (as in earlier Schroth et al work):\n  - EM/EM: no null or reduced-function alleles.\n  - EM/IM and IM/IM: one or two reduced alleles only, no null alleles.\n  - EM/PM or PM/IM: one null allele (with or without reduced allele).\n  - PM/PM: two null alleles (poor metabolizers).\n- Use of CYP2D6-inhibiting co-medications (e.g., certain SSRIs) was not recorded; such drugs were not recommended for hot flashes in the trial but cannot be excluded.\n\nGenetic quality and allele frequencies:\n- Genotyping success rates: >98% for *4, *6, *10, *41; ~84% for the rarer *3.\n- Observed minor allele frequencies in this largely Caucasian cohort:\n  - *3: q \u2248 0.01\n  - *4: q \u2248 0.21\n  - *6: q \u2248 0.01\n  - *10: q \u2248 0.03\n  - *41: q \u2248 0.09\n- Hardy\u2013Weinberg equilibrium (HWE):\n  - *4, *6, *10 were in HWE (e.g., *4 p=0.07).\n  - Deviations for *3 (p=0.003) and *41 (p=0.009) were modest. Authors suggest possible contribution from somatic deletion at 22q13 or ungenotyped *5 deletions leading to an apparent heterozygote deficit.\n- Importantly, the clinically key *4 allele\u2014central to previous controversies\u2014was in HWE, supporting genotyping validity, in contrast to strong HWE deviations reported in some earlier large trials (e.g., BIG 1-98, ATAC).\n\nClinical characteristics:\n- 166 cases/287 controls from Arm A; 153 cases/270 controls from Arm B.\n- Median age ~66\u201369 years; most had stage I disease (\u224861%) and node-negative status (~62%). All tumors were hormone receptor\u2013positive; HER2 positivity was low (~7%). No major imbalances between cases and matched controls across arms due to strict matching.\n- First events among 319 cases: ~28% distant recurrence, ~13% local recurrence, ~9% contralateral breast cancer, ~29% second (non-breast) primary, ~25% death.\n\nPrimary pharmacogenomic findings (years 0\u20135 by arm):\n- Analysis: conditional logistic regression for matched sets, examining odds of a disease event according to CYP2D6 phenotype.\n\nArm A (5 years tamoxifen monotherapy):\n- PM/PM vs EM/EM:\n  - OR 2.45 (95% CI 1.05\u20135.73), p=0.04.\n  - Indicates significantly higher odds of an early disease event in CYP2D6 poor metabolizers.\n- EM/PM or PM/IM vs EM/EM (\u22651 null allele but not PM/PM):\n  - OR 1.67 (95% CI 0.95\u20132.93), p=0.07 (trend toward higher risk).\n- EM/IM or IM/IM vs EM/EM (only reduced-function alleles, no null alleles):\n  - OR 1.23 (95% CI 0.58\u20132.61), p=0.60 (no evidence of increased risk).\n- Interpreted as a gene\u2013dose effect for null alleles: greatest risk in two-null (PM/PM), intermediate in one-null, minimal in reduced-only genotypes.\n\nArm B (2 years tamoxifen \u2192 3 years anastrozole, 0\u20135 years combined):\n- PM/PM vs EM/EM:\n  - OR 0.60 (95% CI 0.15\u20132.37), p=0.47.\n- EM/PM or PM/IM vs EM/EM:\n  - OR 0.76 (95% CI 0.43\u20131.31), p=0.32.\n- EM/IM or IM/IM vs EM/EM:\n  - OR 1.02 (95% CI 0.52\u20132.01), p=0.96.\n- No significant association between CYP2D6 phenotype and event risk across the whole 5-year sequence, implying that the detrimental impact seen in Arm A is not apparent when patients switch to anastrozole after 2 years.\n\nTime-window analyses (mechanistic dissection):\nGiven the contrasting results between Arms A and B, the authors split follow-up into the tamoxifen-only period (years 1\u20132) and years 3\u20135 (tamoxifen vs anastrozole):\n\nYears 1\u20132 (all patients on tamoxifen):\n- Events were few, limiting power; estimates are imprecise but directionally consistent.\n- PM/PM vs EM/EM:\n  - Arm A: OR 2.54, p=0.25.\n  - Arm B: OR 2.60, p=0.46.\n- These point estimates suggest higher early risk in PM/PM while on tamoxifen, but wide CIs preclude firm conclusions.\n\nYears 3\u20135 (tamoxifen continuation vs anastrozole switch):\n- Restricted to women event-free in first 2 years.\n\nArm A (continued tamoxifen):\n- PM/PM vs EM/EM:\n  - OR 2.40 (95% CI 0.86\u20136.66), p=0.09 (trend toward increased risk).\n- EM/PM or PM/IM vs EM/EM:\n  - OR 1.70 (95% CI 0.91\u20133.17), p=0.09 (trend toward increased risk).\n- Again, directionally consistent with main 0\u20135 year analysis: reduced CYP2D6 activity confers higher risk during ongoing tamoxifen.\n\nArm B (switched to anastrozole):\n- PM/PM vs EM/EM:\n  - OR 0.28, p=0.23.\n- EM/PM or PM/IM vs EM/EM:\n  - OR 0.63, p=0.22.\n- Although not statistically significant, point estimates trend toward *lower* odds of events in PM categories once patients are on anastrozole, suggesting that any disadvantage of low CYP2D6 activity is not only absent but potentially reversed after switching to an AI.\n\nInterpretation and mechanistic implications:\n- Tamoxifen is a prodrug converted by CYP2D6 into endoxifen, a potent anti-estrogen. Prior pharmacokinetic data show a stepwise reduction in plasma endoxifen with increasing burden of null alleles.\n- This analysis supports a pharmacologically coherent model:\n  - During active tamoxifen therapy, women with CYP2D6 PM/PM or one null allele have a higher risk of breast cancer recurrence or related events, consistent with reduced formation of endoxifen.\n  - Reduced-function alleles without null alleles (IM only) have less clear impact.\n  - Once tamoxifen is stopped and therapy is switched to anastrozole (whose metabolism depends primarily on CYP3A and UGTs, not CYP2D6), CYP2D6 genotype no longer predicts worse outcomes and may even show a protective trend.\n- Clinical implication: the apparent \u201cnegative\u201d CYP2D6\u2013tamoxifen associations in some recent large trials may be obscured by inclusion of patients who switched from tamoxifen to an AI; if outcomes are analyzed without segregating tamoxifen-exposure time, a true pharmacogenomic signal present only during tamoxifen administration may be diluted or annulled.\n\nMethodological strengths:\n- Embedded in a randomized clinical trial with standardized endocrine regimens, high-quality clinical outcome data, and no confounding chemotherapy.\n- Rigorous matching of cases and controls on key prognostic factors and exposure time, which improves internal validity and power.\n- Use of tissue sections containing both tumor and normal cells, plus detailed attention to genotyping quality and HWE, which addresses major methodological criticisms of earlier studies.\n- Inclusion of more than half of all early events (214 of 408 first events in first 5 years), making the genotyped sample more representative of the parent tamoxifen population than in some prior analyses (e.g., ATAC\u2019s ~18.9% sample).\n\nKey limitations:\n- Retrospective use of archived tissue; germline DNA (e.g., blood) was not prospectively collected.\n- CYP2D6 *5 deletion and gene duplications were not genotyped, so some metabolizer categorization may be misclassified.\n- No data on concomitant CYP2D6 inhibitors (e.g., certain antidepressants, other medications), which also influence endoxifen levels.\n- Focus on early events (0\u20135 years); the study cannot address whether CYP2D6 genotype influences very late recurrences after endocrine therapy ends.\n- Number of PM/PM patients and some subgroups is modest; some analyses border on statistical significance and require cautious interpretation.\n\nClinical and pharmacogenomic implications:\n- In a well-conducted trial context, CYP2D6 poor metabolizer status (two null alleles) is associated with substantially higher odds of early recurrence or related events for women treated with 5 years of tamoxifen alone.\n- Switching to anastrozole after 2 years appears to mitigate\u2014perhaps negate\u2014the adverse effect of reduced CYP2D6 metabolism, consistent with anastrozole\u2019s CYP2D6-independent pharmacology.\n- For pharmacogenomics practice and trial design:\n  - Analyses of CYP2D6 and tamoxifen need to be stratified by actual tamoxifen exposure and subsequent AI use, rather than lumping all endocrine therapy together.\n  - Future prospective studies could test genotype-guided strategies: e.g., up-front AI therapy, altered tamoxifen dosing, extended AI after shorter tamoxifen, or direct endoxifen administration in patients with reduced CYP2D6 activity.\n  - Measuring circulating endoxifen concentrations may complement genotyping and could be used to individualize therapy.\n\nOverall conclusion:\nThe ABCSG-8 pharmacogenomic substudy supports CYP2D6 as a clinically relevant determinant of tamoxifen effectiveness, but only during periods when tamoxifen is actually being administered. This effect is not observed\u2014and may be reversed\u2014once therapy is switched to anastrozole. The work helps reconcile divergent literature by highlighting the importance of treatment sequencing, exposure windows, and rigorous genotyping methodology when evaluating the CYP2D6\u2013tamoxifen relationship.\n",
    "title": "CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8",
    "pmid": "23213055",
    "var_pheno_ann": [
        {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2D6*3",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": "23213055",
            "Phenotype Category": "efficacy",
            "Significance": "not stated",
            "Notes": "CYP2D6*3 genotyped (2549 delA; minor allele frequency q=0.01) as part of alleles defining poor (null) metabolism; clinical association is reported only at the phenotype-group level, not per individual allele.",
            "Sentence": "CYP2D6*3 is associated with increased likelihood of a disease event when treated with tamoxifen in people with Disease:Breast Cancer.",
            "Alleles": "*3",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Efficacy:Disease event",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "extensive metabolizer genotype (no null or reduced alleles)",
            "Comparison Metabolizer types": null,
            "PMID_norm": "23213055",
            "Variant Annotation ID_norm": "1",
            "Citations": [
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.",
                "In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM ([Table 5](#T5)).",
                "In summary, in the ABCSG 8 clinical trial, the CYP2D6 PM/PM phenotype was associated with a higher likelihood of an early disease event in women treated with 5 years of tamoxifen, but not in patients treated with sequential tamoxifen followed by anastrozole."
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3",
                "variant_id": "PA165816578",
                "confidence": 1.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "CYP2D6*4",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": "23213055",
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "CYP2D6*4 (1846 G>A; q=0.21) is the most common null allele used to define PM phenotype. In Arm A (5 years tamoxifen), PM/PM (two null alleles, mainly *4) had OR=2.45 (95% CI 1.05\u20135.73; p=0.04) for a disease event versus EM/EM. Carriers of at least one null allele (PM/IM or PM/EM) showed OR=1.67 (95% CI 0.95\u20132.93; p=0.07) versus EM/EM.",
            "Sentence": "CYP2D6*4 is associated with increased likelihood of a disease event when treated with tamoxifen in people with Disease:Breast Cancer.",
            "Alleles": "*4",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Efficacy:Disease event",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "extensive metabolizer genotype (no null or reduced alleles)",
            "Comparison Metabolizer types": null,
            "PMID_norm": "23213055",
            "Variant Annotation ID_norm": "2",
            "Citations": [
                "In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM ([Table 5](#T5)). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event.",
                "DNA was assessed for the most common CYP2D6 single nucleotide polymorphisms (SNP) corresponding to alleles associated with null [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] CYP2D6 enzyme activity as previously described ([11](#R11)) using the Applied Biosystems\u2019 Taqman\u00ae Allelic Discrimination Assay (Foster City, CA) with the ABI Prism 7900HT Real Time System according to the manufacturer\u2019s instructions.",
                "CYP2D6 *4 (1846 G>A) ... q=0.21"
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*4",
                "variant_id": "PA165816579",
                "confidence": 1.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "CYP2D6*6",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": "23213055",
            "Phenotype Category": "efficacy",
            "Significance": "not stated",
            "Notes": "CYP2D6*6 (1707 delT; q=0.01) is a null allele contributing to PM phenotype; clinical effects are reported for PM/PM and PM carrier groups but not per allele.",
            "Sentence": "CYP2D6*6 is associated with increased likelihood of a disease event when treated with tamoxifen in people with Disease:Breast Cancer.",
            "Alleles": "*6",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Efficacy:Disease event",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "extensive metabolizer genotype (no null or reduced alleles)",
            "Comparison Metabolizer types": null,
            "PMID_norm": "23213055",
            "Variant Annotation ID_norm": "3",
            "Citations": [
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.",
                "DNA was assessed for the most common CYP2D6 single nucleotide polymorphisms (SNP) corresponding to alleles associated with null [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] CYP2D6 enzyme activity as previously described ([11](#R11)) using the Applied Biosystems\u2019 Taqman\u00ae Allelic Discrimination Assay (Foster City, CA) with the ABI Prism 7900HT Real Time System according to the manufacturer\u2019s instructions.",
                "In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM ([Table 5](#T5)). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event."
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*6",
                "variant_id": "PA165816581",
                "confidence": 1.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "CYP2D6*10",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": "23213055",
            "Phenotype Category": "efficacy",
            "Significance": "not stated",
            "Notes": "CYP2D6*10 (100 C>T plus 1846 G>A; q=0.03) is a reduced-function allele contributing to intermediate metabolizer phenotype; clinical association is modeled for EM/IM and IM/IM groups relative to EM/EM (OR 1.23, 95% CI 0.58\u20132.61; p=0.60) but not per individual allele.",
            "Sentence": "CYP2D6*10 is associated with increased likelihood of a disease event when treated with tamoxifen in people with Disease:Breast Cancer.",
            "Alleles": "*10",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Efficacy:Disease event",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "extensive metabolizer genotype (no null or reduced alleles)",
            "Comparison Metabolizer types": null,
            "PMID_norm": "23213055",
            "Variant Annotation ID_norm": "4",
            "Citations": [
                "DNA was assessed for the most common CYP2D6 single nucleotide polymorphisms (SNP) corresponding to alleles associated with null [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] CYP2D6 enzyme activity as previously described ([11]) using the Applied Biosystems\u2019 Taqman\u00ae Allelic Discrimination Assay (Foster City, CA) with the ABI Prism 7900HT Real Time System according to the manufacturer\u2019s instructions.",
                "CYP2D6 phenotype groups were defined as previously published ([11]) where \u2018extensive\u2019 metabolizers do not carry a null or reduced allele (EM/EM); those with one to two reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \u2018poor\u2019 metabolizers, those with 2 null alleles (PM/PM).",
                "In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM ([Table 5]). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event."
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*10",
                "variant_id": "PA165816582",
                "confidence": 1.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": "23213055",
            "Phenotype Category": "efficacy",
            "Significance": "not stated",
            "Notes": "CYP2D6*41 (2988 A; q=0.09) is a reduced-function allele contributing to intermediate metabolizer phenotype; deviation from HWE noted, but allele frequency similar to other European populations. Clinical outcome reported at phenotype-group level.",
            "Sentence": "CYP2D6*41 is associated with increased likelihood of a disease event when treated with tamoxifen in people with Disease:Breast Cancer.",
            "Alleles": "*41",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Efficacy:Disease event",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "extensive metabolizer genotype (no null or reduced alleles)",
            "Comparison Metabolizer types": null,
            "PMID_norm": "23213055",
            "Variant Annotation ID_norm": "5",
            "Citations": [
                "\"DNA was assessed for the most common CYP2D6 single nucleotide polymorphisms (SNP) corresponding to alleles associated with null [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] CYP2D6 enzyme activity as previously described ([11]) using the Applied Biosystems\u2019 Taqman\u00ae Allelic Discrimination Assay (Foster City, CA) with the ABI Prism 7900HT Real Time System according to the manufacturer\u2019s instructions.\"",
                "\"CYP2D6 phenotype groups were defined as previously published ([11]) where \u2018extensive\u2019 metabolizers do not carry a null or reduced allele (EM/EM); those with one to two reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \u2018poor\u2019 metabolizers, those with 2 null alleles (PM/PM).\"",
                "\"In summary, in the ABCSG 8 clinical trial, the CYP2D6 PM/PM phenotype was associated with a higher likelihood of an early disease event in women treated with 5 years of tamoxifen, but not in patients treated with sequential tamoxifen followed by anastrozole.\""
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*41",
                "variant_id": "PA165816584",
                "confidence": 1.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 6,
            "Variant/Haplotypes": "poor metabolizers",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": "23213055",
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "Women with CYP2D6 PM/PM phenotype (two null alleles, mainly *3, *4, *6) on Arm A (5 years tamoxifen) had OR=2.45 (95% CI 1.05\u20135.73; p=0.04) for disease event versus EM/EM during the first 5 years of therapy.",
            "Sentence": "CYP2D6 poor metabolizers Are associated with increased likelihood of a disease event when treated with tamoxifen in people with Disease:Breast Cancer.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "poor metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Efficacy:Disease event",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": "extensive metabolizer",
            "PMID_norm": "23213055",
            "Variant Annotation ID_norm": "6",
            "Citations": [
                "In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM ([Table 5](#T5)).",
                "Among the post-menopausal women with ER positive breast cancer enrolled on ABCSG 8 who were randomized to 5 years of tamoxifen (Arm A), there was a significantly higher odds of a disease event for those with CYP2D6 PM/PM phenotype relative to those with the CYP2D6 EM/EM phenotype, but this was not observed in patients treated with anastrozole following tamoxifen (Arm B).",
                "In summary, in the ABCSG 8 clinical trial, the CYP2D6 PM/PM phenotype was associated with a higher likelihood of an early disease event in women treated with 5 years of tamoxifen, but not in patients treated with sequential tamoxifen followed by anastrozole."
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "poor metabolizers",
                "variant_id": null,
                "confidence": 0.0
            },
            "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
            }
        },
        {
            "Variant Annotation ID": 7,
            "Variant/Haplotypes": "poor metabolizers",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen, anastrozole",
            "PMID": "23213055",
            "Phenotype Category": "efficacy",
            "Significance": "no",
            "Notes": "In Arm B (2 years tamoxifen then anastrozole), PM/PM phenotype showed no significant association with disease events over 5 years (OR 0.60, 95% CI 0.15\u20132.37; p=0.47) compared with EM/EM.",
            "Sentence": "CYP2D6 poor metabolizers Are not associated with increased likelihood of a disease event when treated with tamoxifen and anastrozole in people with Disease:Breast Cancer.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": "poor metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Efficacy:Disease event",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "and",
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:Breast Cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Alleles or Genotype(s)": null,
            "Comparison Metabolizer types": "extensive metabolizer",
            "PMID_norm": "23213055",
            "Variant Annotation ID_norm": "7",
            "Citations": [
                "Conversely in Arm B, no significant association was found between *CYP2D6* genotype and the likelihood of a disease event during the 5 years of treatment.",
                "During years 3\u20135, for women on Arm A who remained event free during the first 2 years of tamoxifen therapy, PM/PM (OR 2.40, 95% CI: 0.86 to 6.66, p = 0.09) and IM/PM or EM/PM (OR 1.70, 95% CI: 0.91\u20133.17, p=0.09) had a trend towards an increased odds of a disease event relative to EM/EM. In contrast, women on Arm B who remained event-free during the first 2 years of tamoxifen, the odds of disease event for PM/PM (OR 0.28, p = 0.23) and the IM/PM or EM/PM group (OR 0.63, p = 0.22) were found to be non-significantly decreased during years 3\u20135 relative to EM/EM.",
                "In summary, in the ABCSG 8 clinical trial, the CYP2D6 PM/PM phenotype was associated with a higher likelihood of an early disease event in women treated with 5 years of tamoxifen, but not in patients treated with sequential tamoxifen followed by anastrozole."
            ],
            "Variant/Haplotypes_normalized": {
                "normalized": "poor metabolizers",
                "variant_id": null,
                "confidence": 0.0
            },
            "Drug(s)_normalized": {
                "normalized": "anastrozole",
                "drug_id": "PA448432",
                "confidence": 1.0
            }
        }
    ],
    "timestamp": "2025-12-02T03:10:15.233380",
    "prompts_used": {
        "var-drug": "var-drug-v2",
        "var-fa": "improved_v2",
        "study-parameters": "study-parameters-v4",
        "summary": "basic",
        "var-pheno": "var-pheno-v5"
    },
    "term_mappings": {
        "CYP2D6*3": {
            "raw_input": "CYP2D6*3",
            "id": "PA165816578",
            "normalized_term": "CYP2D6*3",
            "url": "https://www.clinpgx.org/haplotype/PA165816578",
            "score": 1.0
        },
        "tamoxifen": {
            "raw_input": "tamoxifen",
            "id": "PA451581",
            "normalized_term": "tamoxifen",
            "url": "https://www.clinpgx.org/chemical/PA451581",
            "score": 1.0
        },
        "CYP2D6*4": {
            "raw_input": "CYP2D6*4",
            "id": "PA165816579",
            "normalized_term": "CYP2D6*4",
            "url": "https://www.clinpgx.org/haplotype/PA165816579",
            "score": 1.0
        },
        "CYP2D6*6": {
            "raw_input": "CYP2D6*6",
            "id": "PA165816581",
            "normalized_term": "CYP2D6*6",
            "url": "https://www.clinpgx.org/haplotype/PA165816581",
            "score": 1.0
        },
        "CYP2D6*10": {
            "raw_input": "CYP2D6*10",
            "id": "PA165816582",
            "normalized_term": "CYP2D6*10",
            "url": "https://www.clinpgx.org/haplotype/PA165816582",
            "score": 1.0
        },
        "CYP2D6*41": {
            "raw_input": "CYP2D6*41",
            "id": "PA165816584",
            "normalized_term": "CYP2D6*41",
            "url": "https://www.clinpgx.org/haplotype/PA165816584",
            "score": 1.0
        },
        "tamoxifen, anastrozole": {
            "raw_input": "tamoxifen, anastrozole",
            "id": "PA448432",
            "normalized_term": "anastrozole",
            "url": "https://www.clinpgx.org/chemical/PA448432",
            "score": 1.0
        }
    }
}